John Chiminski’s Post

I’m grateful to have had the opportunity to explain how Catalent Pharma Solutions is powering a new era of Biopharma innovation at STAT’s "Look Ahead at Biotech in 2022" event. I feel energized about the future of biotech, and as Eli Casdin pointed out during his panel, I’m confident that biotech companies will increasingly partner with CDMOs like Catalent to utilize existing manufacturing capacity instead of building their own.